Making Tomorrow’s
Cancer Treatment Better
We are Isofol
Isofol is a publicly listed biotech company dedicated to developing arfolitixorin, a next-generation folate-based drug candidate designed to enhance the efficacy of standard treatments for patients with severe cancer.
Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.
Isofol’s shares are traded on Nasdaq Stockholm.
Latest press releases
2025-11-14
Interview with Charité – Universitätsmedizin Berlin
Watch the interview with Prof. Sebastian Stintzing who is the principal coordinating investigator in Isofol’s on-going phase Ib/II study.
2025-11-14
Investor Meeting
On November 13 Isofol invited to an investor meeting to provide an update on the company’s ongoing clinical study with the drug candidate arfolitixorin.
2025-10-08
CEO interview
Isofol’s CEO, Petter Segelman Lindqvist, was interviewed by Dagens Industri Investor Relations for an update on the company.
For investors
Upcoming Events
- January 12, 2026 - January 15, 2026
J.P. Morgan Healthcare week, San Francisco, USA
Isofol will be present during J.P. Morgan Healthcare week via Business Sweden and will, among other things, participate in the Team Sweden Networking Breakfast on January 12 at 7:30 AM. - January 21, 2026 - January 21, 2026
Redeye Fight Cancer Day, Stockholm
Isofol attending during this day with a short presentation followed by a live Q&A session with Redeye’s analysts. - February 18, 2026 - February 18, 2026
Year-end report 2025
Latest reports and presentations
